UTILIZATION OF RECOMBINANT INFLUENZA VIRUSES AND MODIFIED VACCINIA ANKARA VIRUS (MVA) WITH GENES THAT ENCODE FOR THE TOXOPLASMA GONDII SAG1 AND SAG2 SURFACE PROTEINS, AS VACCINES AGAINST TOXOPLASMOSIS

The present invention concerns to recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T. gondii parasite SAG1 (MVA) and SAG2 (MVA and inf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: GUIMARAES, FLAVIO FONSECA, MENDES, ERICA ARAUJO, CAETANO, BRAULIA COSTA, BARBOSA, RAFAEL POLIDORO ALVES, MACHADO, ALEXANDRE DE MAGALHAES VIEIRA, GAZZINELLI, RICARDO TOSTES, BRUNA-ROMERO, OSCAR
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The present invention concerns to recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), and to a process for construction of recombinant influenza viruses and modified vaccinia Ankara viruses (MVA) with genes that encode for the T. gondii parasite SAG1 (MVA) and SAG2 (MVA and influenza) proteins, by means of a homologous recombination technique between two transfer vectors (for construction of MVA virus) and reverse genetics (for construction of influenza virus). Additionally, the present invention describes a vaccine composition using recombinant influenza viruses and modified vaccinia Ankara viruses (MVA), or recombinant adenoviruses and modified vaccinia Ankara viruses (MVA), for immunization against infections caused by the T. gondii parasite. Finally, the present invention describes a novel immunization method against infections or tumoral diseases, using recombinant influenza virus and adenovirus, in heterologous protocols of immune response induction and enhancement.